Specific IgG2 antibodies to Pseudomonas aeruginosa lipid A and lipopolysaccharide are early markers of chronic infection in patients with cystic fibrosis
- PMID: 8300245
- DOI: 10.1007/BF01712448
Specific IgG2 antibodies to Pseudomonas aeruginosa lipid A and lipopolysaccharide are early markers of chronic infection in patients with cystic fibrosis
Abstract
The IgG subclass antibody response to the two parts of Pseudomonas aeruginosa lipopolysaccharide; endotoxic lipid A and the O-polysaccharide, were investigated in a retrospective longitudinal study involving 16 patients with cystic fibrosis and chronic P. aeruginosa lung infection. The purpose of the study was to see if any of the IgG subclasses of either specificity could be used as prognostic markers in the development and subsequent course of the lung disease. IgG2 anti-lipid A, IgG3 anti-lipid A, and IgG2 anti-polysaccharide showed a significant positive correlation with deteriorating pulmonary function already before chronic P. aeruginosa lung infection was diagnosed as well as in subsequent years. The findings suggest antigenic exposure of the patient before chronic infection is detected by routine sputum examinations, and further support our previous findings of a critical role of the IgG subclass response in modulating the course of inflammatory lung damage in these patients.
Similar articles
-
Antibody responses to lipid A, core, and O sugars of the Pseudomonas aeruginosa lipopolysaccharide in chronically infected cystic fibrosis patients.J Clin Microbiol. 1992 Jul;30(7):1848-55. doi: 10.1128/jcm.30.7.1848-1855.1992. J Clin Microbiol. 1992. PMID: 1378455 Free PMC article.
-
Quantitative analysis of the IgG and IgG subclass immune responses to chromosomal Pseudomonas aeruginosa beta-lactamase in serum from patients with cystic fibrosis by western blotting and laser scanning densitometry.Thorax. 1996 Jul;51(7):733-8. doi: 10.1136/thx.51.7.733. Thorax. 1996. PMID: 8882082 Free PMC article.
-
Immunoglobulin-G subclasses in cystic fibrosis. IgG2 response to Pseudomonas aeruginosa lipopolysaccharide.Am Rev Respir Dis. 1986 Mar;133(3):418-22. doi: 10.1164/arrd.1986.133.3.418. Am Rev Respir Dis. 1986. PMID: 3082264
-
IgG subclasses and chronic bacterial infection. Subclass antibodies and the clinical course of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis.APMIS Suppl. 1996;66:1-41. APMIS Suppl. 1996. PMID: 8972694 Review. No abstract available.
-
[Chronic Pseudomonas aeruginosa airway colonization in cystic fibrosis patients : Prevention concepts].Internist (Berl). 2017 Nov;58(11):1133-1141. doi: 10.1007/s00108-017-0327-8. Internist (Berl). 2017. PMID: 28963697 Review. German.
Cited by
-
The Association between IgG and Disease Severity Parameters in CF Patients.J Clin Med. 2021 Jul 28;10(15):3316. doi: 10.3390/jcm10153316. J Clin Med. 2021. PMID: 34362100 Free PMC article.
-
The Role of Pseudomonas aeruginosa Lipopolysaccharide in Bacterial Pathogenesis and Physiology.Pathogens. 2019 Dec 19;9(1):6. doi: 10.3390/pathogens9010006. Pathogens. 2019. PMID: 31861540 Free PMC article. Review.
-
Increased severity of respiratory infections associated with elevated anti-LPS IgG2 which inhibits serum bactericidal killing.J Exp Med. 2014 Aug 25;211(9):1893-904. doi: 10.1084/jem.20132444. Epub 2014 Aug 11. J Exp Med. 2014. PMID: 25113975 Free PMC article.
-
Anti-LPS IgA and IgG Can Inhibit Serum Killing of Pseudomonas aeruginosa in Patients with Cystic Fibrosis.Infect Immun. 2021 Nov 16;89(12):e0041221. doi: 10.1128/IAI.00412-21. Epub 2021 Aug 30. Infect Immun. 2021. PMID: 34460286 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical